Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]
News [2620]
Articles [112]
Editorials [3]
Conferences [85]
elearning [27]
ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC
ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC
ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival
ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival
ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy
ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy
New biomarker may guide best use of KRAS inhibitors in lung cancer
New biomarker may guide best use of KRAS inhibitors in lung cancer
ASCO 2025: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumours
ASCO 2025: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumours
ASCO 2025: Study demonstrates improved survival with combination of lurbinectedin and atezolizumab for extensive-stage small cell lung cancer
ASCO 2025: Study demonstrates improved survival with combination of lurbinectedin and atezolizumab for extensive...
Relationship between mutation profile detected by next-generation sequencing and histopathological parameters in lung squamous cell carcinoma
Relationship between mutation profile detected by next-generation sequencing and histopathological parameters in...
New method of taxol production has the potential to greatly reduce the cost
New method of taxol production has the potential to greatly reduce the cost
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
Immune checkpoint inhibitors significantly increase myocarditis risk in NSCLC patients
Immune checkpoint inhibitors significantly increase myocarditis risk in NSCLC patients

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation